Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.60 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11480265 | 0.87 | GSK3B (0.80) | GSK3BALDH1A1HIF1ATRPA1MAPK1 | |
| SCHEMBL5317013 | 0.81 | GSK3B (0.64) | GSK3BALDH1A1HIF1ATRPA1MAPK1 | |
| SCHEMBL10886301 | 0.80 | GSK3B (0.70) | GSK3BALDH1A1HIF1ATRPA1MAPK1 | |
| SCHEMBL11365527 | 0.80 | MAPT (0.56) | ALDH1A1HIF1AMAPK1MEN1KMT2A | |
| SCHEMBL3373429 | 0.78 | LMNA (0.47) | ALDH1A1HIF1AMEN1KMT2AMAPT | |
| SCHEMBL2968369 | 0.78 | GSK3B (0.67) | GSK3BALDH1A1HIF1ATRPA1MAPK1 | |
| SCHEMBL5787064 | 0.78 | GSK3B (0.67) | GSK3BALDH1A1HIF1ATRPA1MAPK1 | |
| SCHEMBL9547546 | 0.78 | LMNA (0.47) | GSK3BHIF1AMEN1KMT2AMAPT | |
| SCHEMBL3181886 | 0.78 | LMNA (0.47) | HIF1AMEN1KMT2AMAPTPOLB | |
| SCHEMBL953871 | 0.78 | GSK3B (1.00) | GSK3BALDH1A1HIF1ATRPA1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116102426-A | Wide-absorption polymerizable ketene photoinitiator and preparation method and application thereof | 合肥工业大学 | 2023-05-12 | — | — | CN | claimed |
| CN-109096126-A | A kind of deuterium-labeled D9The synthetic method of clenobuterol hydrochloride | 东莞暨南大学研究院 | 2018-12-28 | — | — | CN | claimed |
| CN-108929276-A | A method of pyrimidines are prepared by methyl ketone compounds and nitrile compounds | 湖南大学 | 2018-12-04 | — | — | CN | claimed |
| WO-2015157360-A1 | PROCESSES TO MAKE PROTEIN KINASE INHIBITORS | ABBVIE INC. (US) | 2015-10-15 | — | — | WO | claimed |
| EP-0430434-B1 | Process for the preparation of fluoroaromatic and fluoroheteroaromatic compounds | ZENECA LTD (GB) | 1994-09-14 | — | — | EP | claimed |
| EP-0430434-A2 | Process for the preparation of fluoroaromatic and fluoroheteroaromatic compounds | ZENECA LIMITED (GB) | 1991-06-05 | — | — | EP | claimed |
| US-20260070898-A1 | PROCESS FOR THE PREPARATION OF FURAZANOBENZIMIDAZOLES AND CRYSTALLINE FORMS THEREOF | GLIOBLASTOMA FOUND INC (US) | 2026-03-12 | — | — | US | disclosed |
| CN-116102426-B | Wide-absorption polymerizable ketene photoinitiator and preparation method and application thereof | 合肥工业大学 | 2025-04-29 | — | — | CN | disclosed |
| US-20240352007-A1 | PROCESSES FOR THE PREPARATION OF FURAZANOBENZIMIDAZOLES AND CRYSTALLINE FORMS THEREOF | BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL (CH) | 2024-10-24 | — | — | US | disclosed |
| EP-3615529-B1 | PROCESSES FOR THE PREPARATION OF FURAZANOBENZIMIDAZOLES AND CRYSTALLINE FORMS THEREOF | BASILEA PHARMACEUTICA INT AG ALLSCHWIL (CH) | 2024-06-05 | — | — | EP | disclosed |
| US-11891382-B2 | Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof | Basilea Pharmaceutica International AG | 2024-02-06 | — | — | US | disclosed |
| CN-116947836-A | Method for preparing furazanobenzimidazole and crystal forms thereof | 巴斯利尔药物国际股份公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-110536890-B | Method for preparing furazanobenzimidazole and crystal forms thereof | 巴斯利尔药物国际股份公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-0052442-B1 | HETEROCYCLIC COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-09-11 | — | — | EP | disclosed |
| US-4503054-A | VASODILATORS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-03-05 | — | — | US | disclosed |
| US-4423045-A | CARDIOVASCULAR DISORDERS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-12-27 | — | — | US | disclosed |
| US-4407797-A | ANTIULCER AGENT | RHONE-POULENC SANTE (FR) | 1983-10-04 | — | — | US | disclosed |
| EP-0052442-A1 | Heterocyclic compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-05-26 | — | — | EP | disclosed |
| US-4213898-A | FOR POLYACRYLONITRILE | SANDOZ LTD. (CH) | 1980-07-22 | — | — | US | disclosed |
| US-4066637-A | BASIC DIAMINOPYRIDINE-(3)-AZO DYESTUFFS | CIBA-GEIGY CORPORATION (US) | 1978-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891382-B2 | Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof | FANCI, CYP2F1, CYP4F3 | GSK3B 2920/4885ALDH1A1 268/4885HIF1A 2718/4885 |
| US-20240352007-A1 | PROCESSES FOR THE PREPARATION OF FURAZANOBENZIMIDAZOLES AND CRYSTALLINE FORMS THEREOF | FANCI, FANCD2, CYP2F1 | GSK3B 2890/4885ALDH1A1 357/4885HIF1A 2691/4885 |
| US-20260070898-A1 | PROCESS FOR THE PREPARATION OF FURAZANOBENZIMIDAZOLES AND CRYSTALLINE FORMS THEREOF | BRCA1, PRKDC, KIT | GSK3B 946/4885ALDH1A1 848/4885HIF1A 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.